A recent study lead by researchers at Massachusetts General Hospital (MA, USA) has highlighted a novel mechanism behind resistance to angiogenesis inhibitors.
Browsing: angiogenesis inhibitor
A group of researchers may have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.
How are targeted therapies being harnessed to improve patient care in metastatic gastric cancer? Find out more in this peer-reviewed article from Future Oncology.
Liver cancer tumors may become resistant to treatment targeting angiogenesis over time by adapting to steal normal blood vessels from surrounding tissue in a process known as vessel co-option.
A novel combination of a tyrosine kinase inhibitor and a MEK inhibitor has been demonstrated to impede the growth of kidney cancer in preclinical studies.
This review article discusses the current developmental status and future perspectives of various angiokinase inhibitors (isorafenib, sunitinib, motesanib and nintedanib) in NSCLC.
A team of researchers led by investigators from the University of Granada (Spain) have designed a drug that fights cancer stem-like cells (CSCs).
This review discusses an analysis of correlative studies in low-dose metronomic chemotherapy trials.
A study led by Isabel Fabregat from the Institute of Biomedical Research and the University of Barcelona (both Spain), holds the potential to select patients with hepatocellular carcinoma who are unresponsive to sorafenib.
This article emphasises the specific features of neuroendocrine tumors in the lung and focuses on the treatment in advanced disease.